Successes in the early treatment of breast cancer are to be celebrated. But those achievements need not limit the development of further and better treatment for patients. Understanding the disease's wider effects could help bring this about.
RAND Europe conducted a study on the societal impact of early breast cancer. This study was divided into three interconnected phases. This is the summary report of the cross-analysis of data gathered through the three phases.
RAND Europe conducted a study on the societal impact of early breast cancer. This study was divided into three interconnected phases. The first phase was a mapping review on the published literature on the impacts of treatment of early breast cancer.
RAND Europe conducted a study on the societal impact of early breast cancer, divided into three interconnected phases. The third phase was a qualitative study assessing the factors affecting access and delivery of treatment for early breast cancer.
RAND Europe conducted a study on the societal impact of early breast cancer. This study was divided into three connected phases. The second phase was a systematic review on non-clinical outcomes of recurrence after treatment of early breast cancer.
An evaluation of the University College London Hospitals NHS Trust - Macmillan Cancer Support partnership aimed to assess the working of the partnership and its capacity to support the partners' plans to move forward.
The aim of this study was to assess reproducibility of the four-category Breast Imaging Reporting and Data System [BI-RADS] density measure and examine its relationship with a continuous measure of percent density.
Multidisciplinary tumor board meetings are common in cancer care, but limited evidence is available about their benefits. We assessed the associations of tumor board participation and structure with care delivery and patient outcomes.
This report shares research and analyses of claims data related to the design of a payment model for specialty oncology services for possible testing by the Center for Medicare and Medicaid Innovation at the Centers for Medicare & Medicaid Services.
The authors conducted a second structured expert consultation process to rate statements related to the diagnosis, management, and surveillance of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
The purpose of this study was to identify and analyze recently published cases of breast implant-associated anaplastic large cell lymphoma (ALCL), with an emphasis on diagnosis, staging, treatment, and outcomes.
Breast implant-associated anaplastic large cell lymphoma is a rare, nonaggressive cancer that can be treated by removal of the implant and surrounding capsule. Research is needed to identify risk factors; a patient registry would aid this process.